RxDoctor Payments Data

Brandy Raich

Adult Health · Saint Louis, MONPI 1891155768

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,762 of the $5,908 with a category attached, or 80.6%. 27 manufacturers reported payments, led by Cvrx, Inc. at 32.0% of the total. 2025 is the largest year on record at $3,135, 4.6 times the $680 reported in 2021. Among adult health clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,908in general payments, 2019–2025

Across 162 payments — averaging $36.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cvrx, Inc.$2K
  • E.r. Squibb & Sons, L.L.C.$807
  • AstraZeneca$386
  • Novartis$371
  • Abbott$335
  • Siemens Medical Solutions USA, Inc.$260
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$1,13219%
  • Food & beverage$4,76281%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,908 in reported general payments places this provider in the 90th percentile of 555 adult health providers in Missouri.

See all adult health providers in Missouri

Medicare billing

Part B allowed, 2024
$32,736
Medicare patients
285
Services billed
387

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban108$79,271
FarxigaDapagliflozin Propanediol17$22,060
BrilintaTicagrelor13$12,677
EntrestoSacubitril/Valsartan11$12,303
JardianceEmpagliflozin11$7,892
ClopidogrelClopidogrel Bisulfate48$417
Metoprolol Succinate62$392
Furosemide75$315
Atorvastatin Calcium22$241
Losartan Potassium36$197
Rosuvastatin Calcium19$183
Nitroglycerin17$175
Spironolactone27$158
Ezetimibe12$153
Isosorbide Mononitrate ErIsosorbide Mononitrate31$144

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$254$79,271108 claims
AstraZenecaFarxiga, Brilinta$386$34,73730 claims
NovartisEntresto$371$12,30311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 555 adult health providers in Missouri.

Other adult health in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →